文献速递淋巴瘤造血干细胞移植与细胞治疗

原发性中枢神经系统淋巴瘤患者接受大剂量甲氨蝶呤为基础化学免疫治疗后,全脑放疗或自体干细胞移植作为巩固策略:国际结外淋巴瘤研究组-32 2期试验第二次随机化结果

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
PubMed 文献 · Lancet Haematol · 2017-10-17

IELSG32 2期试验第二次随机化纳入118例新诊断原发性中枢神经系统淋巴瘤患者,比较全脑放疗与卡莫司汀-塞替派预处理自体干细胞移植作为巩固治疗。两组2年无进展生存率无显著差异:全脑放疗组80%,移植组69%(HR 1.50,95%CI 0.83-2.71;p=0.17)。两种巩固治疗均可行且有效,移植组血液学毒性更常见,并报告2例感染相关毒性死亡。

要点

  • 全脑放疗与自体干细胞移植巩固的2年无进展生存率无显著差异。
  • 全脑放疗组2年无进展生存率80%,移植组69%(HR 1.50,95%CI 0.83-2.71;p=0.17)。
  • 移植组血液学毒性更常见,2例毒性死亡(感染)均发生在移植组。

核心结论

  • 对于70岁及以下原发性中枢神经系统淋巴瘤患者,大剂量甲氨蝶呤为基础化学免疫治疗后,全脑放疗和自体干细胞移植作为巩固治疗均可行且有效。
  • 治疗决策时应考虑全脑放疗后认知功能障碍的风险和影响。

研究设计与样本

  • IELSG32 是一项国际随机2期试验,第二次随机化比较全脑放疗与卡莫司汀-塞替派预处理自体干细胞移植作为巩固治疗。
  • 2010年2月19日至2014年8月27日从5个国家53个中心招募227例患者,219例可评估;122例符合第二次随机化条件,118例随机分配(每组59例)。
  • 入组为HIV阴性、年龄18-70岁、新诊断原发性中枢神经系统淋巴瘤且ECOG体能状态0-3的患者。
  • 诱导治疗为MATRix方案(甲氨蝶呤、阿糖胞苷、塞替派、利妥昔单抗)等方案,每3周重复,共4个疗程。
  • 第二次随机化在全脑放疗(光子4-10 MeV,每周5次,每次180 cGy,末次诱导化疗后4周内开始)与卡莫司汀-塞替派预处理自体干细胞移植之间进行。

主要发现

  • 全脑放疗组和自体干细胞移植组均达到预设疗效阈值(两组前52例患者中至少40例2年无进展生存)。
  • 2年无进展生存率全脑放疗组为80%(95%CI 70-90),自体干细胞移植组为69%(95%CI 59-79),无显著差异(HR 1.50,95%CI 0.83-2.71;p=0.17)。
  • 两种巩固治疗均耐受良好,4级非血液学毒性不常见;血液学毒性在自体干细胞移植组比全脑放疗组更常见。
  • 共记录2例毒性死亡(感染),均发生在接受自体干细胞移植的患者中。

关键数值与推荐

  • 主要终点为2年无进展生存率,以诱导组和诱导化疗反应为分层参数。
  • 分析基于改良意向性治疗原则。
  • 全脑放疗方案:光子4-10 MeV,每周5次,每次180 cGy,末次诱导化疗后4周内开始。
  • 自体干细胞移植预处理:卡莫司汀第-6天400 mg/m2,塞替派第-5天和第-4天每12小时5 mg/kg,随后回输自体外周血干细胞。

临床怎么用

  • 作者认为,对于70岁及以下原发性中枢神经系统淋巴瘤患者,大剂量甲氨蝶呤为基础化学免疫治疗后,全脑放疗和自体干细胞移植均为可行且有效的巩固治疗。
  • 作者指出,治疗决策时应考虑全脑放疗后认知功能障碍的风险和影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to whole-brain radiotherapy (WBRT), as consolidation after high-dose-methotrexate-based chemoimmunotherapy. METHODS: HIV-negative patients (aged 18-70 years) with newly diagnosed primary CNS lymphoma and an Eastern Cooperative Oncology Group performance status of 0-3 were randomly assigned to receive four courses of methotrexate 3·5 g/m2 on day 1 plus cytarabine 2 g/m2 twice daily on days 2 and 3 (group A); or the same combination plus two doses of rituximab 375 mg/m2 on days -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiotepa 30 mg/m2 on day 4 (group C), with the three groups repeating treatment every 3 weeks. Patients with responsive or stable disease after induction treatment, with adequate autologous peripheral blood stem-cell collection, and without persistent iatrogenic side-effects, were eligible for the second randomisation between WBRT (photons of 4-10 MeV; five fractions per week; fraction size 180 cGy; started within 4 weeks from the last induction course; group D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/m2 on day -6, and thiotepa 5 mg/kg every 12 h on days -5 and -4, followed by reinfusion of autologous peripheral blood stem cells; group E). A permuted block randomised design was adopted for both randomisations, and a computer-generated randomisation list was used within each stratum. No masking after assignment to intervention was adopted. The primary endpoint was 2-year progression-free survival, with induction group and response to induction chemotherapy as stratification parameters. Analyses were done on a modified intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT01011920. FINDINGS: Between Feb 19, 2010, and Aug 27, 2014, 227 patients were recruited from 53 centres in five countries. 219 of 227 enrolled patients were assessable. Of the 122 patients eligible for the second randomisation, 118 patients were randomly assigned to WBRT or ASCT (59 patients per group) and constitute the study population. WBRT and ASCT were both effective, and achieved the predetermined efficacy threshold of at least 40 progression-free survivors at 2 years among the first 52 patients in both groups D and E. There were no significant differences in 2-year progression-free survival between WBRT and ASCT: 80% (95% CI 70-90) in group D and 69% (59-79) in group E (hazard ratio 1·50, 95% CI 0·83-2·71; p=0·17). Both consolidation therapies were well tolerated. Grade 4 non-haematological toxicity was uncommon; as expected, haematological toxicity was more common in patients treated with ASCT than in those who received WBRT. Two toxic deaths (infections) were recorded, both in patients who received ASCT. INTERPRETATION: WBRT and ASCT are both feasible and effective as consolidation therapies after high-dose methotrexate-based chemoimmunotherapy in patients aged 70 years or younger with primary CNS lymphoma. The risks and implications of cognitive impairment after WBRT should be considered at the time of therapeutic decision. FUNDING: Agenzia Italiana del Farmaco, Cancer Research UK, Oncosuisse, and Swiss National Science Foundation.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017. PMID: 29054815. doi:10.1016/S2352-3026(17)30174-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。